Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis.

[1]  M. Caligiuri,et al.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. , 2012, The Journal of clinical investigation.

[2]  Hsien-Da Huang,et al.  MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. , 2012, The Journal of clinical investigation.

[3]  M. Bushell,et al.  microRNAs in cancer management. , 2012, The Lancet. Oncology.

[4]  F. Berger,et al.  MicroRNAs: molecular features and role in cancer. , 2012, Frontiers in bioscience.

[5]  B. Vundinti,et al.  MicroRNAs in hematological malignancies: a novel approach to targeted therapy , 2012, Hematology.

[6]  Xiuming Zhu,et al.  MicroRNA‐122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β‐catenin pathway , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[7]  D. Ichikawa,et al.  Circulating microRNA in digestive tract cancers. , 2012, Gastroenterology.

[8]  P. Qi,et al.  Serum MicroRNAs as Biomarkers for Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection , 2011, PloS one.

[9]  F. Tacke,et al.  Increased liver stiffness denotes hepatic dysfunction and mortality risk in critically ill non-cirrhotic patients at a medical ICU , 2011, Critical care.

[10]  De-sheng Wang,et al.  Altered expression levels of miRNAs in serum as sensitive biomarkers for early diagnosis of traumatic injury , 2011, Journal of cellular biochemistry.

[11]  Laura Beretta,et al.  Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease , 2011, PloS one.

[12]  M. Albitar,et al.  Circulating MicroRNAs as Biomarkers for Hepatocellular Carcinoma , 2011, Journal of clinical gastroenterology.

[13]  Y. Maehara,et al.  Clinical significance and potential of hepatic microRNA‐122 expression in hepatitis C , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[14]  Chen Wu,et al.  Circulating MicroRNAs, miR‐21, miR‐122, and miR‐223, in patients with hepatocellular carcinoma or chronic hepatitis , 2011, Molecular carcinogenesis.

[15]  Yue Wang,et al.  Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. , 2010, Clinical chemistry.

[16]  Andrew P Lewis,et al.  Regulation and biological function of the liver-specific miR-122. , 2010, Biochemical Society transactions.

[17]  Hui Zhou,et al.  Liver‐enriched transcription factors regulate MicroRNA‐122 that targets CUTL1 during liver development , 2010, Hepatology.

[18]  Takahiro Ochiya,et al.  Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis , 2010, Cancer science.

[19]  Peng-jun Zhang,et al.  Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies , 2010, Clinical science.

[20]  S. Lemon,et al.  Regulation of Hepatitis C Virus Translation and Infectious Virus Production by the MicroRNA miR-122 , 2010, Journal of Virology.

[21]  Gunda Millonig,et al.  Liver stiffness is directly influenced by central venous pressure. , 2010, Journal of hepatology.

[22]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[23]  Puneet Puri,et al.  Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression , 2008, Hepatology.

[24]  Michael Niepmann,et al.  microRNA-122 stimulates translation of hepatitis C virus RNA , 2008, The EMBO journal.

[25]  M. Odenthal,et al.  Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR , 2008, Journal of Clinical Pathology.

[26]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[27]  Laurent Castera,et al.  Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.

[28]  H. Bonkovsky,et al.  Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1 and hepatitis C virus genes in human hepatocytes. , 2007, Gastroenterology.

[29]  Chris Sander,et al.  Cellular cofactors affecting hepatitis C virus infection and replication , 2007, Proceedings of the National Academy of Sciences.

[30]  D. Capron,et al.  Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan) , 2006, European journal of gastroenterology & hepatology.

[31]  C. Ripoll,et al.  Antiviral Therapy Decreases Hepatic Venous Pressure Gradient in Patients with Chronic Hepatitis C and Advanced Fibrosis , 2006, The American Journal of Gastroenterology.

[32]  Mark Graham,et al.  miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. , 2006, Cell metabolism.

[33]  N. Rajewsky,et al.  Silencing of microRNAs in vivo with ‘antagomirs’ , 2005, Nature.

[34]  P. Sarnow,et al.  Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA , 2005, Science.

[35]  V. de Lédinghen,et al.  Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. , 2005, Gastroenterology.

[36]  Christos Christidis,et al.  Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C , 2005, Hepatology.

[37]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[38]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[39]  M. Ziol,et al.  Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.

[40]  M. Manns,et al.  A comparison of fibrosis progression in chronic liver diseases. , 2003, Journal of hepatology.

[41]  G. Brundtland.  Reducing Risks to Health, Promoting Healthy Life , 2002 .

[42]  M. Selgelid,et al.  From the World Health Organization. , 2002, JAMA.

[43]  K. Ishak,et al.  Histological grading and staging of chronic hepatitis. , 1995 .

[44]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[45]  B. Maharaj,et al.  SAMPLING VARIABILITY AND ITS INFLUENCE ON THE DIAGNOSTIC YIELD OF PERCUTANEOUS NEEDLE BIOPSY OF THE LIVER , 1986, The Lancet.

[46]  E. Mezey,et al.  Sampling variability on percutaneous liver biopsy. , 1979, Archives of internal medicine.

[47]  Plumley Pf.  Letter: the consultants' contract. , 1975, Lancet.

[48]  H. Eguchi,et al.  Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. , 2012, Journal of hepatology.

[49]  W. Filipowicz,et al.  Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy , 2009, Nature Medicine.

[50]  G. Gerken,et al.  Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C. , 2009, Journal of hepatology.

[51]  M. Odenthal,et al.  Mini Review Article Microrna Are Central Players in Anti-and Profibrotic Gene Regulation during Liver Fibrosis , 2022 .